retatrutide triple agonist glp-1 gip glucagon phase 2 results Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Retatrutide, a TRIPLE agonist (GLP1,

This synergistic combination is why it outperformed earlier GLP-1 monotherapies like semaglutide

This article was created with the assistance of Generative AI and has undergone editorial review before publishing.

Genetic factors, baseline metabolic health, dietary compliance, physical activity levels, and even gut microbiome composition likely contribute to this variability

& Currie, P

Alongside aesthetic and safety outcomes, practitioners should consider recording patients weight at each visit and should assess psychological and psychosocial effects (informally or based on relevant questionnaires) in order to build a holistic understanding of progress and patient wellness

doi: 10.1073/pnas.88.16.7224